DDX53 and malaria: Indeed, while CT26 TCTP cells were refractory to cisplatin as reported previously28, these cells were more susceptible to TCTP-targeting agents, especially to DHA, a clinically available drug to treat malaria (CT26 No IC50 = 407.6 uM, CT26 TCTP IC50 = 22.67 μM, about 20-fold) (Fig. 6a).